Ezra Cohen to Neoplasms
This is a "connection" page, showing publications Ezra Cohen has written about Neoplasms.
Connection Strength
1.871
-
The Changing Landscape of Therapeutic Cancer Vaccines-Novel Platforms and Neoantigen Identification. Clin Cancer Res. 2021 02 01; 27(3):689-703.
Score: 0.253
-
A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors. J Immunother Cancer. 2019 12 04; 7(1):342.
Score: 0.238
-
Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients. Clin Cancer Res. 2013 Jun 01; 19(11):3059-67.
Score: 0.150
-
Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients. Clin Cancer Res. 2012 Sep 01; 18(17):4785-93.
Score: 0.143
-
A phase I study of sirolimus and bevacizumab in patients with advanced malignancies. Eur J Cancer. 2011 Jul; 47(10):1484-9.
Score: 0.130
-
mTOR: the mammalian target of replication. J Clin Oncol. 2008 Jan 20; 26(3):348-9.
Score: 0.105
-
Forthcoming receptor tyrosine kinase inhibitors. Expert Opin Ther Targets. 2006 Dec; 10(6):793-7.
Score: 0.097
-
Eganelisib, a First-in-Class PI3K? Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial. Clin Cancer Res. 2023 06 13; 29(12):2210-2219.
Score: 0.076
-
ONYX-015. Onyx Pharmaceuticals. Curr Opin Investig Drugs. 2001 Dec; 2(12):1770-5.
Score: 0.068
-
Role of B Cells in Responses to Checkpoint Blockade Immunotherapy and Overall Survival of Cancer Patients. Clin Cancer Res. 2021 11 15; 27(22):6075-6082.
Score: 0.066
-
A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2018 08; 82(2):309-317.
Score: 0.054
-
Interdisciplinary Oncology Education: a National Survey of Trainees and Program Directors in the United States. J Cancer Educ. 2018 06; 33(3):622-626.
Score: 0.054
-
Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol. 2016 Mar 20; 34(9):987-1011.
Score: 0.046
-
Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide. Clin Cancer Res. 2015 Nov 15; 21(22):5092-9.
Score: 0.044
-
Pharmacokinetics of single-agent axitinib across multiple solid tumor types. Cancer Chemother Pharmacol. 2014 Dec; 74(6):1279-89.
Score: 0.042
-
Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies. Clin Pharmacol Ther. 2014 Jul; 96(1):27-35.
Score: 0.040
-
A phase Ib trial of LY2584702 tosylate, a p70 S6 inhibitor, in combination with erlotinib or everolimus in patients with solid tumours. Eur J Cancer. 2014 Mar; 50(5):876-84.
Score: 0.040
-
Effects of vascular endothelial growth factor signaling inhibition on human erythropoiesis. Oncologist. 2013; 18(8):965-70.
Score: 0.038
-
The effect of thalidomide on the pharmacokinetics of irinotecan and metabolites in advanced solid tumor patients. Cancer Chemother Pharmacol. 2011 Dec; 68(6):1629-32.
Score: 0.034
-
Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors. Clin Cancer Res. 2011 Jun 01; 17(11):3841-9.
Score: 0.033
-
Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies. Clin Cancer Res. 2011 Apr 01; 17(7):1956-63.
Score: 0.033
-
The next phase of chemoprevention research. Cancer Prev Res (Phila). 2011 Mar; 4(3):293-5.
Score: 0.032
-
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers. Cancer Res. 2010 Mar 15; 70(6):2158-64.
Score: 0.030
-
A Threshold Model for T-Cell Activation in the Era of Checkpoint Blockade Immunotherapy. Front Immunol. 2019; 10:491.
Score: 0.014
-
PI3K? is a molecular switch that controls immune suppression. Nature. 2016 11 17; 539(7629):437-442.
Score: 0.012